{"status":"success","data":{"title":"Fibrinolysis for Acute Pulmonary Embolism","slug":"PE-fibrinolysis","tags":["alteplase","tpa"],"collection":["pulmonary","critical care"],"content":"\n# Fibrinolysis for Acute Pulmonary Embolism (PE)\n\n**Massive PE:** Acute PE with at least 1 of the following:\n\n-   Sustained hypotension from PE itself (SBP &lt; 90 mmHg for ≥ 15 min, or requiring inotropic support)\n-   Pulselessness\n-   Persistent profound bradycardia (HR &lt; 40 bpm with signs/symptoms of shock)\n\n**Submassive PE:** Acute PE without systemic hypotension (SBP ≥ 90 mmHg) but with either RV dysfunction or myocardial necrosis.\n\n-   *RV dysfunction:* the presence of at least 1 of the following:\n\n    -   Echo: RV dilation (apical 4-chamber RV diameter divided by LV diameter &gt; 0.9), or RV systolic dysfunction\n    -   CT: RV dilation (4-chamber RV diameter divided by LV diameter &gt; 0.9)\n    -   BNP &gt; 90 pg/mL\n    -   N-terminal pro-BNP &gt; 500 pg/mL\n    -   ECG changes: New complete or incomplete right BBB, anteroseptal ST elevation or depression, or anteroseptal T-wave inversion\n-   *Myocardial necrosis is defined as either of the following*:\n\n    -   Troponin I &gt; 0.4 ng/mL\n    -   Troponin T &gt; 0.1 ng/mL\n\n**Low Risk PE**: Acute PE and the absence of clinical markers of adverse prognosis that define massive or submassive PE\n\n## Fibrinolysis Recommendations\n\n<table>\n<colgroup>\n<col width=\"50%\" />\n<col width=\"50%\" />\n</colgroup>\n<tbody>\n<tr class=\"odd\">\n<td>Reasonable to give:</td>\n<td>Massive acute PE and acceptable risk of bleeding complications.</td>\n</tr>\n<tr class=\"even\">\n<td>Consider giving it:</td>\n<td>Submassive acute PE with clinical evidence of adverse prognosis (new hemodynamic instability, worsening respiratory insufficiency, severe RV dysfunction, or major myocardial necrosis) and low risk of bleeding complications.</td>\n</tr>\n<tr class=\"odd\">\n<td>Not recommended:</td>\n<td><ul>\n<li>Low-risk PE</li>\n<li>Submassive acute PE with minor RV dysfunction, minor myocardial necrosis, and no clinical worsening</li>\n<li>Undifferentiated cardiac arrest</li>\n</ul></td>\n</tr>\n</tbody>\n</table>\n\n## Fibrinolytic dosing\n\n**Alteplase** 100 mg IV over 2 hours.\n-   Consider contraindications for Alteplase when deciding to proceed with Rx\n-   Currently, only FDA approved agents for PE are urokinase, streptokinase, and alteplase. Tenecteplase studies in progress.\n\n## References\n\n-   [Sharifi M, Bay C, Skrocki L, Rahimi F, Mehdipour M; “MOPETT” Investigators. Moderate pulmonary embolism treated with thrombolysis (from the \"MOPETT\" Trial). Am J Cardiol. 2013 Jan 15;111(2):273-7.](http://www.ncbi.nlm.nih.gov/pubmed/?term=23102885)\n-   [Jaff MR et al. Management of massive and submassive pulmonary embolism, iliofemoral deep vein thrombosis, and chronic thromboembolic pulmonary HTN. Circulation. 2011;123(16):1788-830.](http://circ.ahajournals.org/content/123/16/1788.full)\n"}}